SEC v. Derek R. Taller Alleges Taller Misappropriated $500,000 From Investor Funds Through Misleading Representations
The Securities and Exchange Commission ("SEC") has initiated a legal action against Derek R. Taller, alleging securities fraud and breaches of fiduciary duty. The complaint asserts that Taller, through his control over Vision BioBanc Holdings, LLC and StHealth Capital Investment Corporation, engaged in a series of fraudulent schemes, resulting in significant financial misappropriations and undisclosed transactions that violated various provisions of federal securities laws.
Central to the SEC's allegations are claims that Taller misrepresented critical financial and corporate governance information in offering documents, leading to approximately $22 million in investor funds being raised under false pretenses concerning board and auditor participation. The SEC further alleges that Taller directed substantial loans totaling around $21.875 million to entities in which he held an undisclosed financial interest, resulting in total losses for investors, including $19.3 million loaned to Company A and $2.375 million to Company B (Compl. ¶102-103).
In addition, the complaint details how stealthy financial manipulations were organized through entities controlled by Taller, such as Consorcia Management LLC and VBB Management Advisory LLC, contributing to further fiduciary breaches and fraud (Compl. ¶72-74). Among other troubling acts, Taller allegedly directed Company B and Company C to purchase cryptocurrency assets without board approval (Compl. ¶111-112). To aid personal gains, the offering documents (PPMs) contained false statements claiming auditing by Accounting Firm A, purported to have "Big Four" status, which misled investors (Compl. ¶42-47).
Another significant concern relates to the manipulation of investor funds, purportedly diverting $280,000 from StHealth Capital for Taller's improper expenses and an additional $500,000 collectively misappropriated from Vision Holdings and StHealth Capital to address Taller's financial interests (Compl. ¶53-54, ¶128-130). The misuse of investor funds extended further with $300,000 from Vision Holdings to repay StHealth Capital, along with $200,000 directed from Vision Holdings to VBB Management, which Taller then allegedly used to purchase crypto assets (Compl. ¶121-122, ¶128, ¶133-138).
The SEC seeks a permanent injunction against Taller, disgorgement of ill-gotten gains, and civil monetary penalties, alongside a prohibition from serving as an officer or director of any registered securities company. The allegations remain unproven, and no response has yet been filed by the defendant.
Mechanism of Alleged Fraud by Taller
The Securities and Exchange Commission (SEC) alleges that Derek R. Taller engaged in a broad range of fraudulent activities while controlling Vision BioBanc Holdings, LLC and StHealth Capital Investment Corporation. The complaint asserts that Taller's misrepresentations and deceptive practices, notably through false information conveyed via private placement memoranda (PPMs), led to significant financial misconduct.
The PPMs distributed by Taller allegedly contained false claims of Board oversight and audit processes to attract investments. The SEC further alleges that Taller orchestrated improper loan transactions totaling approximately $21.875 million to companies in which he had undisclosed financial interests, including $1.8 million directed to Company A and a $200,000 convertible promissory note investment in Company A (Compl. ¶93-94, ¶102-103).
The complaint accuses Taller of misappropriating funds from managed entities. Throughout this period, Vision Holdings operated without any functional Board oversight until August 2021, during which time Taller purportedly had unilateral control over decisions, compounding the impact of his alleged fraudulent activities (Compl. ¶39, ¶88).
Financial Figures Involved
The SEC's complaint against Derek R. Taller outlines several financial transactions central to the allegations of securities fraud and breach of fiduciary duty. According to the filing, between January 2020 and October 2022, Taller allegedly misappropriated funds from entities he controlled, with improper expenses and undisclosed transactions leading to conflicts of interest. $280,000 was improperly billed to StHealth Capital, while an independent audit conclusively revealed improper reimbursements amounting to $286,966 (Compl. ¶128-130). The SEC claims these transactions occurred without proper disclosure, potentially deceiving investors and violating federal securities laws.
Parties and Entities
The plaintiff in this case is the Securities and Exchange Commission (SEC), which has brought a complaint against Derek R. Taller, who stands accused of managing fraudulent schemes through entities under his control. Taller, the defendant, is alleged to have managed Vision BioBanc Holdings, LLC ("Vision Holdings") and StHealth Capital Investment Corporation ("StHealth Capital"), both of which are purportedly central to his fraudulent activities.
The complaint contends that StHealth Capital was deemed a business development company while Vision Holdings served as an unregistered fund, both controlled at the leadership level by Taller. These entities allegedly acted in concert to facilitate unauthorized transactions benefiting Taller's personal interests.
Further details in the complaint reveal that Company A, Company B, and Company C were also involved in the purported schemes. According to the complaint, Taller held undisclosed financial interests connected to these companies: an approximately 2% interest in Company A through a trust established in the name of his family members, and undisclosed fee rights relating to Company B and Company C through his firm Consorcia (Compl. ¶106, ¶109, ¶153-154). The complaint details how loans were directed to these companies, resulting in substantial financial improprieties and breaches of fiduciary duties.
This case highlights the interconnectedness of numerous entities under Taller's domain, which the SEC claims were utilized to perpetuate fraudulent practices and mislead investors. The intricate relationships among these parties and entities form the foundation of the SEC's allegations against Taller.
Claims Against Taller (Securities Act and Exchange Act)
The SEC's complaint alleges that Derek R. Taller violated Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act, along with its implementing Rule 10b-5, through deceptive practices associated with his management of Vision BioBanc Holdings, LLC and StHealth Capital Investment Corporation. According to the filing, from 2019 through 2022, Taller engaged in a pattern of securities fraud to mislead investors about the oversight and financial health of these entities.
Advisers Act and Investment Company Act Violations
The Securities and Exchange Commission's complaint against Derek R. Taller includes allegations of violations under the Advisers Act and the Investment Company Act, focusing on Taller's roles and actions as an investment adviser. According to the complaint, Counts 3 and 4 allege violations of the Advisers Act §§206(1) and 206(2) and Investment Company Act §57(a)(4) alongside Rule 17d-1 (Compl. ¶150-155). These sections pertain to fiduciary duties and prohibited transactions involving affiliated persons.
Specifically, the complaint asserts that Taller knowingly or recklessly engaged in schemes or artifices that defrauded clients, which constitutes a direct violation of the Advisers Act (Compl. ¶151-152). The alleged misconduct includes failing to disclose conflicts of interest and misusing investor funds without proper oversight.
Additionally, the SEC alleges that Taller’s actions violated the Investment Company Act by engaging in transactions considered joint enterprises or profit-sharing plans with affiliated persons under §57(a)(4). Count 4 of the complaint states that these transactions were executed without required approval from an independent board or the SEC, further amplifying the breach of fiduciary duties outlined (Compl. ¶153-154). The SEC's allegations underline the absence of transparency and proper governance in financial dealings, critical aspects in maintaining fiduciary integrity under these regulatory frameworks.
The complaint underscores that these alleged violations resulted in significant financial misappropriations and management fees being directed to Taller's entities, all while breaching standards imposed on advisers under federal securities laws. The assertive misconduct allegedly violated the stringent duties imposed by the Investment Company Act, aiming to prevent conflicts of interest and safeguard investor capital.
Relief Sought and Procedural Posture
The complaint filed by the Securities and Exchange Commission (SEC) against Derek R. Taller requests several forms of judicial relief aimed at addressing alleged misconduct. Key among these is a permanent injunction designed to prevent Taller from future violations of the Securities Act, Exchange Act, and related regulations.
The proceedings remain in the early stages, with no defendant response filed at this time.
The allegations described here are taken from the filing and remain unproven; no responsive pleading is reflected in the source document.
From the Complaint Public Court Record
Thomas P. Smith, Jr. Alison Conn Todd D. Brody Wesley W. Wintermyer Attorneys for Plaintiff SECURITIES AND EXCHANGE COMMISSION New York Regional Office 100 Pearl Street, Suite 20-100 New York, NY 10004-2616 (212) 336-0080 (Brody) brodyt@sec.gov UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK SECURITIES AND EXCHANGE COMMISSION, Plaintiff, -against- DEREK R. TALLER, Defendant. COMPLAINT 25 Civ. 3537 ( ) JURY TRIAL DEMANDED Plaintiff Securities and Exchange Commission (“Commission” or “SEC”), for its Complaint against Defendant Derek R. Taller (“Taller”), alleges as follows: SUMMARY 1. Between January 2020 and October 2022 (the “Relevant Period”), Taller engaged in persistent and egregious fraudulent conduct while managing and advising two separate investment vehicles—an unregistered fund, Vision BioBanc Holdings, LLC (“Vision Holdings”), and a business development company, StHealth Capital Investment Corporation (“StHealth Capital”). 2. During 2020, while Chief Executive Officer (“CEO”) of Vision Holdings, Taller disseminated offering documents to prospective investors containing multiple material misrepresentations concerning the oversight and supervision of Vision Holdings, including: (1) that
2 Vision Holdings’ investment objectives and portfolio valuations would be subject to supervision by Vision Holdings’ Board of Directors; (2) that Vision Holdings’ financial statements would be audited by one of the “Big Four” accounting firms (“Accounting Firm A”), which it named; and (3) that the auditor’s work would be reviewed by Vision Holdings’ Audit Committee. In fact, Vision Holdings operated without a functioning Board of Directors for more than a year and a half after it started raising money from investors, never engaged an independent auditor, and did not have an audit committee. Taller had ultimate authority over these offering documents. 3. In addition, as an investment adv
Questions about this topic: david@newmanbrunk.com